Hormone Research · 2008 · 17 citations · 0 references
MedicineEndocrinologyPharmacotherapyBone MetabolismPediatric EndocrinologyPediatric TherapeuticsBone GrowthChild GrowthGrowth DisordersGrowth HormoneGrowth Hormone TherapyTurner SyndromeGrowth Hormone Effects On BoneGrowth VelocityGrowth Velocity AssessmentHeight Growth MeasurementPediatric Bone EndocrinologyPubertal Bone DevelopmentPubertal Growth VelocityTurner Syndrome Treatment
22 girls with Turner syndrome aged 10.8 +/- 2.4 years with bone age 8.58 +/- 1.32 years, randomized in two groups, were treated for 3 years with either growth hormone (GH), 0.1 U/kg daily (group A), or GH, 0.1 U/kg, plus oxandrolone, 0.06 mg/kg (group B). This resulted in a sharp increase in growth rate for the first year of treatment, followed in the second and third years by a growth rate near to the normal mean for age. The growth velocity was better in group B, the difference being significant during the first year only. After 3 years, the predicted adult height had increased by 2.1 cm as a mean in group A and by 4.5 cm in group B, with important individual variations, resulting in a gain of at least 3 cm in 3/10 patients of group A and 9/12 of group B. No metabolic or other side effects occurred. These 3-year data confirm that GH improves the predictable height in Turner girls. They suggest that it may be useful for at least 3 years and that adding a small dose of oxandrolone for 2 years in girls aged more than 8 years could be of good practice. However, earlier and more protracted treatment with GH has to be studied with the hope to better improve the predictable adult height.